{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:23:35Z","timestamp":1780496615668,"version":"3.54.1"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1704184"],"award-info":[{"award-number":["U1704184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114144","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T02:17:39Z","timestamp":1642645059000},"page":"114144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs"],"prefix":"10.1016","volume":"231","author":[{"given":"Yuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114144_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1035902","article-title":"Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein","volume":"16","author":"Kuzmichev","year":"2002","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2022.114144_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular mechanisms directing PRC2 recruitment and H3K27 methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.molcel.2014.12.020","article-title":"Jarid2 methylation via the PRC2 complex regulates H3K27me3 deposition during cell differentiation","volume":"57","author":"Sanulli","year":"2015","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114144_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1101\/gad.173930.111","article-title":"PRC2 directly methylates GATA4 and represses its transcriptional activity","volume":"26","author":"He","year":"2012","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2022.114144_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114144_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.gde.2009.03.001","article-title":"Biochemical mechanisms of gene regulation by polycomb group protein complexes","volume":"19","author":"Muller","year":"2009","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejmech.2022.114144_bib8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.jmb.2016.10.012","article-title":"The multiple facets of PRC2 alterations in cancers","volume":"429","author":"Wassef","year":"2017","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jgg.2021.03.013","article-title":"Polycomb-group proteins in the initiation and progression of cancer","volume":"58","author":"Zhao","year":"2021","journal-title":"J.\u00a0Genet. Genomics"},{"key":"10.1016\/j.ejmech.2022.114144_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc.2016.83","article-title":"Maintaining cell identity: PRC2-mediated regulation of transcription and cancer","volume":"16","author":"Comet","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114144_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tibs.2019.04.005","article-title":"Emerging roles for polycomb-group proteins in stem cells and cancer","volume":"44","author":"Chan","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2022.114144_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13543776.2021.1841167","article-title":"Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)","volume":"31","author":"Dockerill","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114144_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114144_bib14","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2022.114144_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.drudis.2018.07.002","article-title":"Khan, Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators","volume":"24","author":"Danishuddin","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114144_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2022.114144_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114144_bib18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2022.114144_bib19","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114144_bib20","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","volume":"59","author":"Vaswani","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13148-021-01045-1","article-title":"Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2022.114144_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s12325-020-01379-x","article-title":"The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review","volume":"37","author":"Rugo","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2022.114144_bib23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114144_bib24","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","article-title":"EZH2-Targeted therapies in cancer: hype or a reality","volume":"80","author":"Eich","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114144_bib25","doi-asserted-by":"crossref","first-page":"32646","DOI":"10.18632\/oncotarget.5066","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors","volume":"6","author":"Baker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114144_bib26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The noncanonical role of EZH2 in cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114144_bib27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib28","doi-asserted-by":"crossref","first-page":"13323","DOI":"10.1074\/jbc.M117.787572","article-title":"Polycomb repressive complex 2 in an autoinhibited state","volume":"292","author":"Bratkowski","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib29","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1126\/science.aac4383","article-title":"Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2","volume":"350","author":"Jiao","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114144_bib30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.molcel.2018.03.020","article-title":"Allosteric activation dictates PRC2 activity independent of its recruitment to chromatin","volume":"70","author":"Lee","year":"2018","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib31","doi-asserted-by":"crossref","first-page":"13805","DOI":"10.1074\/jbc.R117.800367","article-title":"Structure, mechanism, and regulation of polycomb-repressive complex 2","volume":"293","author":"Moritz","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature08398","article-title":"Role of the polycomb protein EED in the propagation of repressive histone marks","volume":"461","author":"Margueron","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114144_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1101\/gad.544410","article-title":"Polycomb complexes act redundantly to repress genomic repeats and genes","volume":"24","author":"Leeb","year":"2010","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2022.114144_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.molcel.2014.12.009","article-title":"Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions","volume":"57","author":"Xu","year":"2015","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib35","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","article-title":"Going beyond Polycomb: EZH2 functions in prostate cancer","volume":"40","author":"Park","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114144_bib36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2017.7","article-title":"Structure of the PRC2 complex and application to drug discovery","volume":"38","author":"Shi","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114144_bib37","doi-asserted-by":"crossref","first-page":"15344","DOI":"10.1021\/acs.jmedchem.0c01344","article-title":"Small molecule approaches for targeting the polycomb repressive complex 2 (PRC2) in cancer","volume":"63","author":"Martin","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114144_bib39","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/srep01911","article-title":"PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer","volume":"3","author":"Sato","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114144_bib40","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-16-0164","article-title":"Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114144_bib41","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-4024","article-title":"EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy","volume":"25","author":"Puppe","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114144_bib42","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1541-7786.MCR-14-0034","article-title":"EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma","volume":"12","author":"Gao","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114144_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-017-0547-3","article-title":"The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter","volume":"11","author":"Gan","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114144_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114144_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2022.114144_bib46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114144_bib47","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114144_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","article-title":"Noncanonical functions of the polycomb group protein EZH2 in breast cancer","volume":"191","author":"Anwar","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2022.114144_bib49","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2022.114144_bib50","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114144_bib51","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib52","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/MCB.00162-07","article-title":"Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells","volume":"27","author":"Shi","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib53","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1038\/onc.2016.453","article-title":"TRIM28 interacts with EZH2 and SWI\/SNF to activate genes that promote mammosphere formation","volume":"36","author":"Li","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114144_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2013.08.028","article-title":"PAF and EZH2 induce Wnt\/beta-catenin signaling hyperactivation","volume":"52","author":"Jung","year":"2013","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41416-019-0538-y","article-title":"EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness","volume":"121","author":"Tabbal","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114144_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/15592294.2019.1633867","article-title":"EZH2 upregulates the PI3K\/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia","volume":"14","author":"Kosalai","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.ejmech.2022.114144_bib57","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","article-title":"EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair","volume":"39","author":"Koyen","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114144_bib58","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899599","article-title":"EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis","volume":"38","author":"Zhao","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2022.114144_bib59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-019-0615-2","article-title":"Engaging chromatin: PRC2 structure meets function","volume":"122","author":"Chammas","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114144_bib60","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.molcel.2018.01.039","article-title":"Unique structural platforms of Suz12 dictate distinct classes of PRC2 for chromatin binding","volume":"69","author":"Chen","year":"2018","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083737","article-title":"Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114144_bib62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10930-018-9785-7","article-title":"WD40 repeat proteins: signalling scaffold with diverse functions","volume":"37","author":"Jain","year":"2018","journal-title":"Protein J."},{"key":"10.1016\/j.ejmech.2022.114144_bib63","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.str.2007.08.007","article-title":"Structural basis of EZH2 recognition by EED","volume":"15","author":"Han","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2022.114144_bib64","doi-asserted-by":"crossref","first-page":"19266","DOI":"10.1073\/pnas.1008937107","article-title":"Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)","volume":"107","author":"Xu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114144_bib65","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1038\/ncomms11316","article-title":"Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114144_bib66","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.tig.2020.12.006","article-title":"Polycomb gene silencing mechanisms: PRC2 chromatin targeting, H3K27me3 'readout', and phase separation-based compaction","volume":"37","author":"Guo","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.ejmech.2022.114144_bib67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41594-018-0023-y","article-title":"Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes","volume":"25","author":"Poepsel","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib68","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1126\/science.aar5700","article-title":"Structures of human PRC2 with its cofactors AEBP2 and JARID2","volume":"359","author":"Kasinath","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114144_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1101\/gad.325050.119","article-title":"PRC2 is high maintenance","volume":"33","author":"Yu","year":"2019","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2022.114144_bib70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114144_bib71","doi-asserted-by":"crossref","first-page":"22152","DOI":"10.1073\/pnas.1911775116","article-title":"PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor","volume":"116","author":"Diehl","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114144_bib72","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1021\/acs.jmedchem.1c00226","article-title":"Polycomb repressive complex 2 modulation through the development of EZH2-EED interaction inhibitors and EED binders","volume":"64","author":"Tomassi","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1021\/acs.jmedchem.6b01473","article-title":"Structure-guided design of EED binders allosterically inhibiting the epigenetic polycomb repressive complex 2 (PRC2) methyltransferase","volume":"60","author":"Lingel","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib74","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1021\/acs.jmedchem.6b01576","article-title":"Discovery of first-in-class, potent, and orally bioavailable embryonic Ectoderm development (EED) inhibitor with robust anticancer efficacy","volume":"60","author":"Huang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib75","doi-asserted-by":"crossref","first-page":"17146","DOI":"10.1021\/acs.jmedchem.1c01161","article-title":"Diverse, potent, and efficacious inhibitors that target the EED subunit of the polycomb repressive complex 2 methyltransferase","volume":"64","author":"Bagal","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib76","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acs.jmedchem.0c00479","article-title":"EEDi-5285: an exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic Ectoderm development","volume":"63","author":"Rej","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib77","doi-asserted-by":"crossref","first-page":"14540","DOI":"10.1021\/acs.jmedchem.1c01059","article-title":"Discovery of EEDi-5273 as an exceptionally potent and orally efficacious EED inhibitor capable of achieving complete and persistent tumor regression","volume":"64","author":"Rej","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib78","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-19-0428","article-title":"An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response","volume":"79","author":"Dong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114144_bib79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nchembio.2306","article-title":"The EED protein\u2013protein interaction inhibitor A-395 inactivates the PRC2 complex","volume":"13","author":"He","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1021\/acscombsci.6b00174","article-title":"Discovery of peptidomimetic ligands of EED as allosteric inhibitors of PRC2","volume":"19","author":"Barnash","year":"2017","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.ejmech.2022.114144_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib82","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1021\/jm501230c","article-title":"Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2","volume":"57","author":"Kong","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib83","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1021\/acs.jmedchem.0c02261","article-title":"Structure-guided development of small-molecule PRC2 inhibitors targeting EZH2-EED interaction","volume":"64","author":"Du","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib84","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.7150\/thno.49235","article-title":"Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2022.114144_bib85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chembiol.2019.11.006","article-title":"Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader","volume":"27","author":"Potjewyd","year":"2020","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","article-title":"EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex","volume":"27","author":"Hsu","year":"2020","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib87","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/pro.3647","article-title":"Polycomb repressive 2 complex-Molecular mechanisms of function","volume":"28","author":"Kouznetsova","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2022.114144_bib88","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/leu.2012.146","article-title":"EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms","volume":"26","author":"Ueda","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114144_bib89","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1021\/acs.jmedchem.7b00287","article-title":"Allosteric inactivation of polycomb repressive complex 2 (PRC2) by inhibiting its adapter protein: embryonic ectodomain development (EED)","volume":"60","author":"Yang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107406","article-title":"Targeting epigenetic machinery: emerging novel allosteric inhibitors","volume":"204","author":"Ye","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114144_bib91","article-title":"Discovery and molecular basis of a diverse set of polycomb repressive complex 2 inhibitors recognition by EED","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114144_bib92","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED","volume":"13","author":"Qi","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib93","article-title":"Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase","volume":"39","author":"DH","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114144_bib94","series-title":"Use of Triazolopyrimidine, Triazolopyridine Compounds and Composition Thereof for Treating PRC2-Mediated Diseases","author":"Zhou","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114144_bib95","series-title":"Pyridine or Pyridazine Cyclic Compound and Application Thereof in Preparing Drugs for Treating Cancer Diseases or Disorders","author":"Zou","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114144_bib96","series-title":"Pyrimidine-or Pyrazine-Based Compound and Application Thereof","author":"Zou","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114144_bib97","series-title":"Preparation of Dihydrobenzofuranylmethylaminoimidazopyrimidine Derivatives for Use as PRC2 Inhibitors","author":"Marx","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114144_bib98","first-page":"2134","article-title":"Rapid identification of novel allosteric PRC2 inhibitors","volume":"14","author":"Read","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib99","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bmcl.2017.02.030","article-title":"SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding","volume":"27","author":"Curtin","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114144_bib100","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114144_bib101","first-page":"307","article-title":"Astemizole: an old anti-histamine as a new promising anti-cancer drug, anti-cancer","volume":"11","author":"Janice","year":"2011","journal-title":"Agent. Mech."},{"key":"10.1016\/j.ejmech.2022.114144_bib102","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/s41401-019-0248-2","article-title":"AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition","volume":"40","author":"Zhang","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114144_bib103","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFR(L858R\/T790M) and EGFR(L858R\/T790M\/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114144_bib104","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.18632\/oncotarget.3790","article-title":"Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114144_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105615","article-title":"Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseases","volume":"169","author":"Tu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114144_bib106","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1158\/1055-9965.EPI-08-0528","article-title":"Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study","volume":"17","author":"Shimizu","year":"2008","journal-title":"Cancer Epidem. Biomark."},{"key":"10.1016\/j.ejmech.2022.114144_bib107","first-page":"3190","article-title":"Anticancer natural coumarins as lead compounds for the discovery of new drugs","volume":"17","author":"Pinto","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib108","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/aps.2017.59","article-title":"Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors","volume":"39","author":"Zhu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114144_bib109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/cpb.c19-00550","article-title":"Identification and assessments of novel and potent small-molecule inhibitors of EED\u2013EZH2 interaction of polycomb repressive complex 2 by computational methods and biological evaluations","volume":"68","author":"Zhu","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2022.114144_bib110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10822-021-00378-6","article-title":"Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method","volume":"35","author":"Misawa","year":"2021","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2022.114144_bib111","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","article-title":"Small-molecule modulation of protein homeostasis","volume":"117","author":"Burslem","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2022.114144_bib112","doi-asserted-by":"crossref","first-page":"15448","DOI":"10.1002\/anie.202004310","article-title":"Prey for the proteasome: targeted protein degradation-A medicinal chemist's perspective","volume":"59","author":"Luh","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114144_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.685106","article-title":"Opportunities and challenges of small molecule induced targeted protein degradation","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib114","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114144_bib115","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib116","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114144_bib117","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/cmdc.202100393","article-title":"LYTACs: an emerging tool for the degradation of non-cytosolic proteins","volume":"16","author":"Ramadas","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114144_bib118","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective Autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114144_bib119","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nchembio.597","article-title":"Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins","volume":"7","author":"Neklesa","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib120","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib121","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114144_bib122","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-021-00245-x","article-title":"The PROTACtable genome","volume":"20","author":"Schneider","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114144_bib123","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target"},{"key":"10.1016\/j.ejmech.2022.114144_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112539","article-title":"PROTAC: a promising technology for cancer treatment","volume":"203","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114144_bib126","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.6b01912","article-title":"Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds","volume":"61","author":"Chan","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib127","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114144_bib128","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/MCB.00307-13","article-title":"Elements of the polycomb repressor SU(Z)12 needed for histone H3-K27 methylation, the interface with E(Z), and in\u00a0vivo function","volume":"33","author":"Rai","year":"2013","journal-title":"Mol. Cell Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:35:33Z","timestamp":1759329333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":128,"alternative-id":["S0223523422000460"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114144","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114144"}}